Skip to main content

Table 1 Baseline pathogens and resistance rate for each treatment sequence

From: Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI)

PathogensFrequency of baseline pathogensaResistance rate by pathogens
CAZ-AVI + metronidazolebCeftolozane/Tazobactam + metronidazolebMeropenemb
Escherichia coli81%1%0%c1%
Streptococcus anginosus group15%0%c0%c0%c
Klebsiella pneumoniae13%1%52%d52%
Bacteroides fragilis12%0%c0%c0%c
Pseudomonas aeruginosa11%7%7%e24%
  1. CAZ-AVI = ceftazidime-avibactam.
  2. aFive most frequently identified baseline pathogens in the RECLAIM study
  3. b2017 resistance data for Italy, calculated from forecast model [17, 20], and expert opinion
  4. cAssumption, due to lack of evidence
  5. dGiven that ceftolozane/tazobactam has no coverage for K. pneumoniae carbapenemase (KPC), the base case was assumed using the resistance rate of K. pneumoniae to carbapenems
  6. eExpert opinion